SIGMAR1 and COVID-19: Targeting Sig-1R is identified as a potential drug repurposing approach to treat COVID-19 patients that, unlike virus-targeted antiviral agents, addresses adaptive cellular mechanisms of host cells that are crucial for viral infection.